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Abstract
Introduction: Polymyositis (PM) and dermatomyositis (DM) are chronic inflammatory muscle diseases, in which
chemokines are thought to contribute to inflammatory cell migration into muscle. In this study, we retrospectively
analyzed the expressions of CX3CL1/fractalkine and its corresponding receptor, CX3CR1, in muscle and lung with
interstitial lung disease (ILD) of PM patients and DM patients, and determined the correlation between serum
soluble CX3CL1 level and disease activity.
Methods: Expressions of CX3CL1 and CX3CR1 in muscle and lung tissue were analyzed by immunohistochemistry.
Serum CX3CL1 concentrations were measured by ELISA. For evaluation of patients’ disease activity, serum
creatinine kinase, manual muscle testing, and the alveolar-arterial oxygen pressure difference were used
independently.
Results: CX3CL1 was expressed on infiltrated mononuclear cells and endothelial cells in muscle affected by PM
and DM and in lung with ILD, whereas CX3CR1 was expressed on some CD4+ T cells, a majority of CD8+ T cells,
and most macrophages in muscle, and on infiltrated mononuclear cells in the lung. Serum soluble CX3CL1 was
significantly higher in PM patients and DM patients than in healthy controls. The CX3CL1 level was correlated with
serum creatinine kinase and manual muscle testing score. In patients with PM and DM with ILD, serum CX3CL1
was also correlated with alveolar-arterial oxygen pressure difference. Furthermore, CX3CL1 was significantly
decreased after conventional treatment.
Conclusions: The interaction between CX3CL1 and CX3CR1 might contribute to the inflammatory cell infiltration
into affected muscle and lung with ILD in PM patients and DM patients. Serum CX3CL1 level could be a surrogate
marker of disease activity.
Introduction
Polymyositis (PM) and dermatomyositis (DM) are
chronic inflammatory diseases affecting skeletal muscle
with infiltration of mononuclear cells, such as CD4 and
CD8 T cells and macrophages [1]. The infiltrating cells
might contribute to the pathogenesis of PM and DM by
releasing cytokines and cytotoxic molecules, such as
TNF, perforin, and granzyme [2,3].
Patients with PM and patients with DM commonly
show proximal muscle weakness, and some patients
exhibit complication of interstitial lung disease (ILD),
which may be associated with rapidly progressive
respiratory insufficiency leading to death [4,5]. Serum
creatinine kinase (CK) is helpful in evaluating both myo-
sitis activity and its response to the treatment. In some
patients, however, serum levels of CK do not correspond
to clinical disease activity [6,7]; moreover, the CK level
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does not correlate with ILD activity. Determining a new
biomarker that is correlated with the activity of myositis
and ILD is therefore useful.
Chemokines are known as important factors for cellu-
lar recruitment into inflamed tissues [8]. CX3CL1/frac-
talkine, a unique CX3C chemokine, exists in two forms:
a membrane-bound form and a soluble form [9-11].
CX3CR1, a unique receptor for CX3CL1, is expressed
on peripheral blood CD4+ and CD8+ T cells that pro-
duce cytotoxic molecules and type 1 cytokines, as well
as on monocytes [12-14]. Since cytotoxic T cells and
macrophages invade the affected muscle in patients with
PM and in patients with DM [15], interaction between
CX3CL1 and CX3CR1 may contribute to the inflamma-
tory cell migration into muscle.
We previously reported that CX3CL1 was expressed
in affected muscle in a murine model of experimental
autoimmune myositis (EAM) and that CX3CR1 was
expressed on the infiltrated CD4+ and CD8+ T cells
and macrophages in the muscle [16]. We also found
that the treatment of EAM mice with anti-CX3CL1
mAb significantly improved the myositis [16]. The
interaction between CX3CL1 and CX3CR1 has there-
fore been suggested to perhaps probably play an
important role in the pathogenesis of murine EAM. In
this study, we aimed to determine the expressions of
CX3CL1 and CX3CR1 in muscle and lung with ILD in
PM patients and DM patients and to investigate the




Serum, muscle, or lung specimens were collected from a
total of 38 patients with PM and with DM who were
admitted to Tokyo Medical and Dental University Hos-
pital or to collaborating medical centers between 2001
and 2009 because of an active newly diagnosed form or
flaring up of the disease. Tables 1 and 2 show the char-
acteristics of the patients in this study. PM and DM
were diagnosed according to the criteria developed by
Bohan and Peter [17,18].
ILD was diagnosed by clinical findings as follows: fine
crackles, exertional dyspnea, nonproductive cough, and
reticular shadow on chest radiographs or ground-glass
opacity on chest high-resolution computed tomography.
The disease activity was defined as symmetrical and
proximal muscle weakness with serum CK elevation, or
gradual or rapidly progressive ILD accompanied by the
findings described above. Patients who also exhibited
other connective tissue diseases, malignancies, infec-
tions, and hemophagocytic syndrome were excluded
from this study. The experimental protocol was
approved in advance by the Ethics Committee of Tokyo
Medical and Dental University.
Immunohistochemistry
Muscle specimens from five patients (two PM patients
and three DM patients) were obtained by muscle biopsy
from deltoid or biceps brachii. One of the five patients
was also analyzed for the serum sample. Three control
Table 1 Characteristics of the patients with polymyositis/dermatomyositis for serum analysis
Healthy control serum (n = 20) PM/DM patient serum (n = 29)
Number of PM/DM 7/22
Number of males/females 9/11 9/20
Age (years) 38.6 ± 2.1 55.3 ± 2.5
Duration of the disease (months) 21.6 ± 8.2
Number of cases of new onset/flare 23/6
Number of antinuclear antibody-positive 9 (n = 22)
Number of anti-Jo-1 antibody-positive 8 (n = 22)
Serum creatinine kinase (IU/l)a 4,063.8 ± 1,466.9
Manual muscle testing score 39.0 ± 1.4 (n = 18)
Number of patients with ILD 19
AaDO2 with ILD 31.5 ± 7.9 (n = 19)
Treatment at time of blood sampling
Untreated 19
Prednisolone alone 4
Prednisolone and cyclosporine 5
Prednisolone and methotrexate 1
Data presented as n or mean ± standard error of the mean. Antinuclear antibody was analyzed by immunofluorescence assay. The titer of anti-Jo-1 antibody was
investigated by enzyme immunoassay. Although in some patients anti-dsDNA (n = 17), anti-RNP (n = 13), anti-Scl-70 (n = 4), and anti-SS-A (n = 12) antibodies
and rheumatoid factor (n = 16) were analyzed, they were all negative. AaDO2, alveolar-arterial oxygen pressure difference; ILD, interstitial lung disease; PM/DM,
polymyositis/dermatomyositis. aNormal range: male < 197 IU/l, female < 180 IU/l.
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muscle samples were obtained from patients with
increased serum CK of unknown etiology. No abnor-
mal histological changes, such as small fiber or inflam-
matory cell infiltration, were observed in the control
specimens. The specimens were frozen immediately in
chilled isopentane precooled in liquid nitrogen, and
then cryostat sections 6 μm thick were prepared. To
analyze CX3CL1 expression, after fixing in cold acet-
one, the sections were treated with 1.5% H2O2 in
methanol for 15 minutes, and then with 5% normal
goat serum in PBS for 30 minutes. The sections were
incubated with 5 μg/ml mouse anti-human CX3CL1
mAb (51637.11; R&D Systems, Minneapolis, MN,
USA) or isotype-matched control mAb at 4°C over-
night. CX3CL1 expression was detected using the
Envision+ kit (Dako, Carpinteria, CA, USA). Diamino-
benzidine chromogen and a buffered substrate were
used for visualization. The sections were counter-
stained with hematoxylin. For double-staining with
CD4, CD8, or CD68, as well as CX3CR1, the sections
were incubated with 10 μg/ml mouse anti-human CD4
mAb (34930; R&D Systems), 1:20 diluted mouse anti-
human CD8 mAb (HIT8a; BD Biosciences, San Jose,
CA, USA), 1:100 diluted mouse anti-human CD68
mAb (KP-1; Dako), or control mAbs at 4°C overnight.
Subsequently, the samples were incubated with 5 μg/
ml Alexa Fluor® 488-conjugated goat anti-mouse IgG
(Molecular Probes, Eugene, OR, USA) for 1 hour at
room temperature. For CX3CR1 staining, the sections
were incubated with 5 μg/ml rabbit anti-human
CX3CR1 antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) or normal rabbit IgG for 2 hours at
room temperature. Next, the samples were incubated
with 5 μg/ml Alexa Fluor® 568-conjugated goat anti-
rabbit IgG (Molecular Probes) for 1 hour at room tem-
perature. The slides were examined using fluorescent
microscopy (BZ-Analyzer; Keyence, Tokyo, Japan).
Lung specimens from six patients (three PM patients
and three DM patients) were obtained by video-
assisted thoracic surgery. One of the six patients was
also analyzed for the serum sample. Two control lung
tissues were obtained by lobectomy for removal of pri-
mary lung tumors. No histological evidence of intersti-
tial disease was found in any of the resected tissue
samples. Paraffin-embedded tissues were deparaffinized
and treated with 0.3% H2O2, followed by incubation
with Protein Block (Dako) and an avidin/biotin block-
ing kit (Vector, Burlingame, CA, USA). The sections
were incubated with 2 μg/ml mouse anti-CX3CL1
mAb (81513; R&D Systems) or 2 μg/ml rabbit anti-
CX3CR1 antibody (Abcam, Cambridge, MA, USA) at
4°C overnight. After washing, they were incubated with
biotin-conjugated rabbit anti-mouse IgG (Dako) or
goat anti-rabbit IgG (Dako) for 30 minutes at room
temperature, followed by the addition of peroxidase-
conjugated streptavidin (Nichirei, Tokyo, Japan) for 5
minutes. Peroxidase activity was visualized using dia-
minobenzidine. Sections were counterstained with
hematoxylin.
Measurement of serum level of CX3CL1
Serum samples were collected from a total of 29
patients (seven PM patients and 22 DM patients) and
20 healthy controls. Fourteen of the patients (three PM
patients and 11 DM patients) were traceable after the
treatment (six patients with prednisolone alone, two
patients with prednisolone + intravenous cyclophospha-
mide, two patients with prednisolone + cyclosporin,
three patients with prednisolone + tacrolimus, and one
patient with prednisolone + intravenous immunoglobu-
lin). The median time of observation was 44.5 months.
The concentration of serum CX3CL1 was measured
using an ELISA kit (DuoSet; R&D Systems) in accor-
dance with the manufacturer’s protocol. All samples
were stored at -80°C before use. The samples were
assayed in duplicate.
Table 2 Characteristics of the patients with polymyositis/
dermatomyositis for muscle and lung analysis
PM/DM patients (n = 11)
Muscle (n = 5) Lung (n = 6)
Number of PM/DM 2/3 3/3
Number of males/females 2/3 1/5
Age (years) 60.4 ± 5.3 59.8 ± 4.3
Duration of the disease (month) 17.6 ± 13.4 20.8 ± 13.2
Number of cases of new onset/
flare
4/1 3/3
Number of antinuclear antibody-
positive
1 (n = 4) 1 (n = 5)
Number of anti-Jo-1 antibody-
positive
0 (n = 4) 1 (n = 5)
Serum creatinine kinase (IU/l)a 2,946.4 ±
1,195.4
141.4 ± 57.4 (n =
5)
Manual muscle testing score 54.3 ± 5.8 (n =
4)
NA
Number of patients with ILD 4 6
AaDO2 with ILD NA 22.7 ± 6.6 (n = 5)
Treatment at time of biopsy
Untreated 4 4
Prednisolone alone 0 2
Prednisolone and cyclosporine 1 0
Data presented as n or mean ± standard error of the mean. Antinuclear
antibody was analyzed by immunofluorescence assay. The titer of anti-Jo-1
antibody was investigated by enzyme immunoassay. Although in some
patients, anti-dsDNA (n = 1 and n = 2 for muscle and lung samples,
respectively), anti-RNP (n = 1 and n = 2), anti-Scl-70 (n = 1 and n = 2), and anti-
SS-A (n = 1 and n = 4) antibodies and rheumatoid factor (n = 2 and n = 4) were
analyzed, they were all negative. AaDO2, alveolar-arterial oxygen pressure
difference; ILD, interstitial lung disease; NA, not available; PM/DM, polymyositis/
dermatomyositis. aNormal range: male < 197 IU/l, female < 180 IU/l.
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Assessment of muscle strength
To evaluate the muscle weakness of patients with myo-
pathy, manual muscle testing (MMT) was measured
using a 0-point to 5-point scale. The technique is sum-
marized elsewhere [19]. We selected 10 muscles includ-
ing deltoid, biceps, triceps, quadriceps, and hamstring,
both right and left sides, and the maximum point score
was 50, which indicates full muscle strength. The MMT
data and serum sample were available from 18 patients
(six PM patients and 12 DM patients).
Statistical analysis
Differences in the levels of CX3CL1 between patients
with PM, patients with DM, and healthy controls were
examined for statistical significance using the Kruskal-
Wallis test. To compare serum CX3CL1 before and
after treatment, the Wilcoxon signed-rank test was
employed. Pearson correlation coefficient was used to
examine the relationship between the level of CX3CL1
and serum CK, MMT score, or the alveolar-arterial oxy-
gen pressure difference (AaDO2). All data are expressed
as mean ± standard error of the mean. The difference
between groups was considered significant when P <
0.05.
Results
Expressions of CX3CL1 and CX3CR1 in muscle in PM and
DM patients
We examined the expression of CX3CL1 in the affected
muscle tissues in patients with PM and patients with
DM by immunohistochemistry. CX3CL1 was not
detected in control samples (Figure 1A). In contrast,
CX3CL1 was expressed on infiltrated mononuclear cells
in the muscle of those with PM and with DM (Figure
1C and 1E, respectively). CX3CL1 was also expressed on
endothelial cells in the inflamed tissues of those with
PM and with DM (Figure 1G and data not shown,
respectively).
We next examined CX3CR1 expression on the infil-
trated mononuclear cells in patients with PM and
patients with DM by double immunohistochemical
staining. In PM, a few CD4+ T cells expressed CX3CR1
(Figure 2A to 2C). The majority of CD8+ T cells and
most CD68-positive macrophages expressed CX3CR1 in
the inflamed tissues of patients with PM (Figure 2D to
2F and 2G to 2I, respectively). Similar CX3CR1 expres-
sion on the infiltrated mononuclear cells was observed
in the muscle of DM patients (data not shown). Table 3
shows the expression of CX3CL1 and CX3CR1 in the
muscle tissue from each of the patients.
Expressions of CX3CL1 and CX3CR1 in lung with ILD in
PM and DM patients
CX3CL1 and CX3CR1 expressions in the lung tissue with
ILD of PM patients and of DM patients were also ana-
lyzed by immunohistochemistry. CX3CL1 was expressed
on the infiltrated mononuclear cells, alveolar macro-
phages, epithelial cells, and endothelial cells in those with
PM (Figure 3C and 3E). CX3CR1 was expressed on the
infiltrated cells, alveolar macrophages, and epithelial cells
in those with PM (Figure 3I and 3K). CX3CL1 and
CX3CR1 were also similarly expressed in the lung with
ILD of DM patients (data not shown). In contrast, lung
tissues of control samples expressed virtually no CX3CL1
and CX3CR1 (Figure 3A and 3G, respectively). Table 4
A B C D
GFE H
Figure 1 CX3CL1 expressions in affected muscle of patients with polymyositis and patients with dermatomyositis. Muscle specimens
from (A, B) controls, (C, D, G, H) polymyositis (PM) patients, and (E, F) dermatomyositis (DM) patients were stained with anti-CX3CL1 mAb (A,
C, E, G) or an isotype-matched control mAb (B, D, F, H). Original magnification, ×200.
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shows the expression of CX3CL1 and CX3CR1 in the
lung tissue from each of the patients.
Serum levels of soluble CX3CL1 in patients with PM and
with DM
We examined the concentrations of serum CX3CL1 in
patients with PM and in DM patients, as well as in
healthy controls. Serum CX3CL1 in PM patients and
DM patients, who had an active newly diagnosed
form or flaring up of the disease, was markedly
increased compared with that in healthy controls (P <
0.01) (Figure 4A). Although the serum CX3CL1 in
PM patients tended to be higher than that in DM
patients, the difference was not statistically significant
(Figure 4A).
To evaluate the effect of treatment on serum
CX3CL1, the serum CX3CL1 levels of 14 traceable
patients with PM and with DM were analyzed before
and after treatment. All patients were treated with oral
corticosteroids and/or immunosuppressants, and were
in remission after the treatment. In all of the patients,
the CX3CL1 level was decreased after treatment (P <
0.01) (Figure 4B). Although serum CX3CL1 was also
compared between the patients with ILD and without
ILD, CX3CL1 levels were not significantly different
(serum concentration of CX3CL1: patients with ILD,
7,457.9 ± 1,341.9 pg/ml; patients without ILD, 5,960.9
± 2,376.3 pg/ml).
To determine whether the serum CX3CL1 level could
be a biomarker of the disease activities of PM and of




Figure 2 CX3CR1 expressions in affected muscle of patients with polymyositis. The muscle tissues of polymyositis (PM) patients were
double-stained with CD4, CD8, or CD68, as well as CX3CR1, and were analyzed with fluorescent microscopy: (A) CX3CR1, (B) CD4, (C) merged
(A) and (B), (D) CX3CR1, (E) CD8, (F) merged (D) and (E), (G) CX3CR1, (H) CD68, and (I) merged (G) and (H). Arrows indicate double-positive
cells. Original magnification, ×400.
Table 3 Expression of CX3CL1 and CX3CR1 in the muscle
tissue from each of the patients
Polymyositis Dermatomyositis




++ +++ +++ ++++ +++
Endothelial cells ++ ++ +++ +++ +++
CX3CR1
CD4+ T cells + + + + +











Muscle tissue sections were scored: -, no staining; +, few of the cells positively
stained; ++, some (less than one-half) of the cells stained; +++, approximately
one-half of the cells stained; ++++, more than one-half of the cells stained; +
++++, most cells stained.
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CX3CL1 and serum CK or MMT score, which are
thought to be markers of myositis activity. As shown in
Figure 5A and 5B, serum CX3CL1 in patients with PM
and patients with DM was significantly correlated with
CK (r = 0.48, P < 0.01) and with MMT score (r = 0.62,
P < 0.01). Among the 29 patients, 19 patients exhibited
complication of ILD. The correlation between the serum
CX3CL1 level and AaDO2 calculated from arterial blood
gas [(713 × FiO2) - (PaCO2/0.8) - PaO2] was also analyzed
in the patients with ILD. Serum CX3CL1 was significantly
correlated with AaDO2 in patients with PM and DM with
ILD (r = 0.64, P < 0.01) (Figure 5C).
Discussion
In this study, we found that CX3CL1 was expressed on
infiltrated mononuclear cells and endothelial cells, and
that its corresponding receptor, CX3CR1, was expressed
on infiltrated inflammatory cells in muscle and lung
with ILD in PM patients and DM patients. The serum
CX3CL1 level was markedly increased in patients with
PM and patients with DM, and was correlated with the
titer of serum CK and the MMT score, and also with
the AaDO2 in patients with ILD complication. These
results suggest that interaction between CX3CL1 and
CX3CR1 might play an important role in inflammatory
cell migration into muscle, as well as lung with ILD, in
patients with PM and patients with DM; furthermore,
the level of serum CX3CL1 could be a biomarker of dis-
ease activity.
Chemokines are thought to play an essential role in
inflammatory cell migration into inflamed tissues. In






















Figure 3 CX3CL1 and CX3CR1 expressions in lung with ILD in polymyositis patients. Lung specimens from (A, B, G, H) controls and (C to
F and I to L) polymyositis (PM) patients with ILD were stained with anti-CX3CL1 mAb (A, C, E), anti-CX3CR1 antibody (G, I, K), or isotype-
matched control antibodies (B, D, F, H, J, L). Arrows indicate the positive infiltrated mononuclear cells (I), alveolar macrophages (M), vascular
endothelial cells (V), and epithelial cells (E). Original magnification, ×400.
Table 4 Expression of CX3CL1 and CX3CR1 in the lung
tissue from each of the patients
Polymyositis Dermatomyositis
Pt1 Pt2 Pt3 Pt1 Pt2 Pt3
CX3CL1
Infiltrated mononuclear cells 50.8 20.6 12.1 42.3 19.8 13.9
Alveolar macrophages 79.6 71.1 58.3 78.1 53.4 78.6
Epithelial cells 59.5 34.6 53.9 48.3 31.3 45.3
Endothelial cells 22.1 23.6 17.0 17.9 13.8 9.4
CX3CR1
Infiltrated mononuclear cells 31.8 20.8 23.4 33.0 21.1 44.2
Alveolar macrophages 77.0 70.4 47.0 73.0 54.1 68.2
Epithelial cells 49.5 72.6 59.8 76.5 39.6 38.9
Percentage frequency of CX3CL1 and CX3CR1 expression in each cell type in
each of the patients.
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Figure 4 Serum level of CX3CL1 in patients with polymyositis, patients with dermatomyositis and healthy controls. Serum samples
were collected from polymyositis (PM) patients (n = 7), dermatomyositis (DM) patients (n = 22) and healthy controls (n = 20). (A) Concentration
of serum soluble CX3CL1 measured by ELISA. Values are mean ± standard error of the mean. (B) CX3CL1 levels before and after treatment in PM
and DM patients (n = 14; three PM patients and 11 DM patients). Symbols joined by a solid line represent data from an individual subject.
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Figure 5 Correlation of serum CX3CL1 level and the disease activity of polymyositis and dermatomyositis. Correlations of the level of
CX3CL1 with (A) serum creatinine kinase (CK) level (n = 29), (B) manual muscle testing (MMT) score (n = 18) in patients with polymyositis (PM)
and patients with dermatomyositis (DM), and (C) the alveolar-arterial oxygen pressure difference (AaDO2) (n = 19) in patients with PM and with
DM complicated by ILD. Each point represents an individual sample.
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infiltrated mononuclear cells and endothelial cells in the
muscle of PM patients and DM patients. Cytotoxic T
cells, including CD4+ and CD8+ T cells, have been
reported to invade the muscle fibers in PM patients and
DM patients [1], while we previously reported that per-
ipheral blood CX3CR1+ T cells express type 1 cytokines
and cytotoxic molecules [12,13]. In addition, CX3CR1 is
expressed on peripheral blood monocytes [14]. Indeed,
CD4+ and CD8+ T cells and macrophages in the
inflamed muscle of PM patients and DM patients
expressed CX3CR1. We therefore consider that the
interaction between CX3CL1 and CX3CR1 might induce
migration of cytotoxic T cells and macrophages, which
is partly involved in the pathogenesis of the diseases,
into affected muscle. Moreover, it was reported that
CX3CL1 provides survival signals and costimulates the
production of proinflammatory cytokines and the release
of granules [20]. CX3CL1 therefore contributes not only
to inflammatory cell accumulation but also to stimula-
tion in the muscle. Our earlier data showed that
CX3CL1 and CX3CR1 were expressed in murine EAM
and that inhibition of CX3CL1 ameliorated myositis
[16]. Taken together, these findings suggest that
CX3CL1 might play an important role in myositis, and
therefore that blockade of CX3CL1 might be therapeuti-
cally beneficial for patients with PM and patients with
DM.
The level of serum soluble CX3CL1 obtained from
patients with active PM and DM was increased, and the
CX3CL1 level was markedly decreased after immuno-
suppressive therapy. Moreover, the CX3CL1 level was
significantly associated with the serum CK level and
MMT score, which are indicative of myositis [21,22].
The serum CX3CL1 level could therefore be a biomar-
ker of disease activity. Increased CX3CL1 in inflamed
muscle might induce the migration of CX3CR1-expres-
sing inflammatory cells - including type 1 cytokines, and
cytotoxic molecule-expressing T cells and macrophages
- into the tissue, and these cells, in turn, express TNFa
and IFNg, which induce additional CX3CL1 expression
on endothelial cells [23] and also on recruited inflam-
matory cells. As a result of these expansive cascades,
CX3CL1 is highly expressed in the inflamed muscle, and
the serum CX3CL1 level might consequently be
increased.
We also found that the serum CX3CL1 level in both
PM patients and DM patients with the complication of
ILD was significantly associated with the AaDO2.
CX3CL1 was expressed on the infiltrated mononuclear
cells, endothelial cells, alveolar macrophages, and epithe-
lial cells in the affected lung tissues. CX3CR1 was also
expressed on infiltrated mononuclear cells, alveolar
macrophages, and epithelial cells. The interaction
between CX3CL1 and CX3CR1 might be involved in the
inflammatory cell infiltration into lung tissue. In addi-
tion, CX3CL1 may stimulate CX3CR1-positive cells for
survival, production of cytokines, and release of granules
in the lung. Serum CX3CL1 was not significantly differ-
ent between the patients with ILD and those without
ILD. Not only ILD, but also muscle inflammation, may
affect the serum CX3CL1 level.
Serum CCL17 has been reported to be increased in
DM patients with ILD [24]. Serum levels of CCL2,
CCL3, CCL8, CXCL10, CXCL11, IL-6, and IL-18 have
also been shown to be correlated with the disease activ-
ity of DM [25-27]. In this study, we showed that serum
CX3CL1 correlated with the serum CK and MMT score
in patients with PM and patients with DM, and also
with the AaDO2 in the patients complicated by ILD.
Serum CX3CL1 was also increased in asthma, sclero-
derma, and rheumatoid arthritis [28-30]. Consequently,
although CX3CL1 is not a disease-specific marker, upon
diagnosis of PM or DM the serum level of CX3CL1
could be a useful marker of disease activity of myositis,
as well as for the complicated ILD.
There are some limitations with CK and MMT as
markers of disease activity, as they may not always fol-
low disease activity. More detailed validation - such as
disease activity tools for use in myositis clinical trials, as
described by the International Myositis Assessment and
Clinical Studies Group [31-33] - may be needed in
future study. Also, samples in this study were retrospec-
tively analyzed; selection biases may therefore influence
the results.
Conclusion
The interaction between CX3CL1 and CX3CR1 might
contribute to the pathogenesis of PM and of DM, and
these could be appropriate molecules for therapeutic
targeting. The serum level of CX3CL1 could be a surro-
gate marker of disease activity.
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